The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Adipogenic Transcriptional Regulation of Hepatic Stellate Cells
Open accessAbstract
Hepatic stellate cells (HSC) undergo transdifferentiation (activation) from lipid-storing pericytes to myofibroblastic cells to participate in liver fibrogenesis. Our recent work demonstrates that depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) constitutes one of the key molecular events for HSC activation and that ectopic expression of this nuclear receptor achieves the phenotypic reversal of activated HSC to the quiescent cells. The present study extends these findings to test a novel hypothesis that adipogenic transcriptional regulation is required for the maintenance of HSC quiescence. Comparative analysis of quiescent and activated HSC in culture reveals higher expression of putative adipogenic transcription factors such as CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBPbeta, C/EBPdelta, PPARgamma, liver X receptor alpha, sterol regulatory element-binding protein 1c and of adipocyte-specific genes in the quiescent cells. Conversely, activated HSC have increased expression of PPARbeta, a transcription factor known to promote fatty acid oxidation. A treatment of activated HSC with the adipocyte differentiation mixture (isobutylmethylxanthine, dexamethasone, and insulin) or ectopic expression of PPARgamma or SREBP-1c in these cells, induces a panel of adipogenic transcription factors, reduces PPARbeta, and causes the phenotypic reversal to quiescent HSC. These results support the importance of adipogenic transcriptional regulation in HSC quiescence and provide a new framework for identifying novel molecular targets for the treatment of liver cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
Adipogenesis and Obesity: Rounding Out the Big Picture
Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,269
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION DURING ADIPOCYTE DIFFERENTIATION
MacDougald, O. A., & Lane, M. D. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.002021 · Cited by 1,061
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism.
Kim, J. B., & Spiegelman, B. M. (1996) · Genes & Development · doi:10.1101/gad.10.9.1096 · Cited by 1,040
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Cited by
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Self-citationRecent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Adipokines in liver diseases #
Marra, F., & Bertolani, C. (2009) · Hepatology · doi:10.1002/hep.23046 · Cited by 471
Myofibroblasts and Fibrosis: Mitochondrial and Metabolic Control of Cellular Differentiation
Gibb, A. A., Lazaropoulos, M. P., & Elrod, J. W. (2020) · Circulation Research · doi:10.1161/circresaha.120.316958 · Cited by 434
Metabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Mechanisms of liver fibrosis and its role in liver cancer
Dhar, D., Baglieri, J., Kisseleva, T., & Brenner, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898141 · Cited by 429
The Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Trivedi, P., Wang, S., & Friedman, S. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.026 · Cited by 427
Gene Expression Profiles During Hepatic Stellate Cell Activation in Culture and In Vivo
De Minicis, S., Seki, E., Uchinami, H., Kluwe, J., Zhang, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.033 · Cited by 426
Jun, J.-I., & Lau, L. F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93563 · Cited by 345
Hepatic stellate cells in physiology and pathology
Kamm, D. R., & McCommis, K. S. (2022) · The Journal of Physiology · doi:10.1113/jp281061 · Cited by 325
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Recent advancement of molecular mechanisms of liver fibrosis
Seki, E., & Brenner, D. A. (2015) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.245 · Cited by 300
Abramovitch, S., Dahan-Bachar, L., Sharvit, E., Weisman, Y., Tov, A. B., Brazowski, E., & Reif, S. (2011) · Gut · doi:10.1136/gut.2010.234666 · Cited by 286
Roles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
Reversibility of liver fibrosis
Sun, M., & Kisseleva, T. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.06.015 · Cited by 274
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270
Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis
Cheng, J. H., She, H., Han, Y.-P., Wang, J., Xiong, S., Asahina, K., & Tsukamoto, H. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00263.2007 · Cited by 258
Self-citationBates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230
Asahina, K., Tsai, S. Y., Li, P., Ishii, M., Maxson, R. E., Sucov, H. M., & Tsukamoto, H. (2009) · Hepatology · doi:10.1002/hep.22721 · Cited by 238
Self-citationCellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis
Mallat, A., & Lotersztajn, S. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00230.2013 · Cited by 211
Ohtani, N., & Kawada, N. (2019) · Hepatology Communications · doi:10.1002/hep4.1331 · Cited by 187
Role for Hedgehog Signaling in Hepatic Stellate Cell Activation and Viability
Sicklick, J. K., Li, Y.-X., Choi, S. S., Qi, Y., Chen, W., Bustamante, M., Huang, J., Zdanowicz, M., Camp, T., Torbenson, M. S., et al. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700349 · Cited by 179
Mechanisms of alcohol‐induced hepatic fibrosis: A summary of the Ron Thurman Symposium†
Purohit, V., & Brenner, D. A. (2006) · Hepatology · doi:10.1002/hep.21107 · Cited by 161
PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells
Zhao, C., Chen, W., Yang, L., Chen, L., Stimpson, S. A., & Diehl, A. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.069 · Cited by 139
Transcriptional regulation of hepatic stellate cells
Mann, J., & Mann, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.011 · Cited by 119
Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand
Li, J., Kuruba, R., Wilson, A., Gao, X., Zhang, Y., & Li, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013955 · Cited by 66
Azzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52
Tian, Y., Sun, D., Liu, N., Zhao, J., Zhao, T., Liu, X., Dong, X., Dong, L., Wang, W., Jiao, P., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03029-8 · Cited by 14
The liver X receptor in hepatic stellate cells: a novel antifibrogenic target?
Mallat, A., & Lotersztajn, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.018 · Cited by 11
Metadata
- Authors
- She, H., Xiong, S., Hazra, S., & Tsukamoto, H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 280
- Issue
- 6
- Pages
- 4959-4967
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2089076289
- Cited by
- 299
- References
- 45
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.